Isodiol International Inc. Signs Partnership Agreement With Kawacatoose First Nation

VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the "Company" or "Isodiol"), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, announces it has signed a partnership agreement with Kawacatoose First Nation (KFN), a leader and forward-thinking Band with operations and land in Saskatchewan, Canada.

Isodiol will partner with the KFN in cultivating and manufacturing high yielding CBD derived from industrial hemp as well as exploring additional economic opportunities with the KFN in commercializing the hemp by-product into everyday finished goods. 

Under the terms of this agreement, KFN will provide up to 3,000 farmable acres of land, as it becomes available and certain conditions are met by both parties on a cost-plus model.  The KFN, with support of Isodiol, will also assemble a Co-op with neighbouring Band's within Saskatchewan, providing economic benefit province wide. 

Marcos Agramont, CEO of Isodiol International Inc. stated, "This is another strong step taken by the Company to expand our footprint in Canada.  The Company will have significant access to the highest quality CBD, as KFN will provide the labour necessary to maintain and improve the farmland. The Company will also provide expert consultation and advice to KFN and the future Co-op on all cultivation methods and standards applicable to the crop to ensure we remain consistent among all of our family of brands."

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol 

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
[email protected]
www.isodiol.com

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.